Elly Usman, Yusticia Katar
Department of Pharmacology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia.
Afr J Infect Dis. 2022 Dec 22;17(1):55-59. doi: 10.21010/Ajidv17i1.5. eCollection 2023.
There is currently no viable pharmaceutical therapy for COVID-19 illness that has been validated. The use of remdesivir is one of the medications for which there is no consistent evidence of a significant therapeutic benefit or a meaningful effect on survival.
The aim of this study was to determine the role of age and comorbidities on the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir at Indonesia's National Referral Hospital.
A retrospective cohort study was used in this study. The subjects in this study were confirmed clinically critical COVID-19 patients who were treated at Dr. M Djamil Hospital Padang, one of Indonesia's national referral hospitals, from January 2 to June 30, 2021. The number of sample size in this study was 90 patients. The variables of this study were divided into three independent variables (age, comorbidities, and a number of comorbidities). A dependent variable was the outcome of confirmed clinically critical COVID-19 patients. The Chi-square test was performed in bivariate analysis, and the odds ratio was calculated. SPSS version 17.0 was used to analyze the data.
The results of this study found that there was an association between ages 50-59 years (OR = 10.23, 95% CI 1.89-55.53), 60-69 years (OR = 4.58, 95% CI 1.25-16.76), and > 70 years (OR = 1.91, 95% CI 1.38 -9.59), comorbid diabetes mellitus (OR = 9.78, 95% CI 1.23-77.66), the number of comorbid > 1 (OR = 10.97, 95% CI 2.19-54.96, and the number of comorbid 1 (OR = 5.69, 95% CI 1.59- 20.41) with the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir.
The significance of age and comorbidities on the outcome of COVID-19 patients treated with remdesivir at Indonesia's national referral hospital was confirmed in this study. This study could assist in the management of patient therapy, potentially decreasing morbidity and even patient mortality.
目前尚无经证实的针对新冠病毒疾病的有效药物疗法。使用瑞德西韦是其中一种药物，但尚无一致证据表明其具有显著治疗益处或对生存率有显著影响。
本研究的目的是确定年龄和合并症对印度尼西亚国家转诊医院接受瑞德西韦治疗的确诊临床重症新冠病毒患者预后的影响。
本研究采用回顾性队列研究。本研究的受试者为2021年1月2日至6月30日在印度尼西亚国家转诊医院之一巴东M·贾米尔博士医院接受治疗的确诊临床重症新冠病毒患者。本研究的样本量为90例患者。本研究的变量分为三个自变量（年龄、合并症和合并症数量）。因变量是确诊临床重症新冠病毒患者的预后。在双变量分析中进行卡方检验，并计算比值比。使用SPSS 17.0版本分析数据。
本研究结果发现，50 - 59岁（比值比 = 10.23，95%置信区间1.89 - 55.53）、60 - 69岁（比值比 = 4.58，95%置信区间1.25 - 16.76）以及70岁以上（比值比 = 1.91，95%置信区间1.38 - 9.59）的年龄、合并糖尿病（比值比 = 9.78，95%置信区间1.23 - 77.66）、合并症数量大于1（比值比 = 10.97，95%置信区间2.19 - 54.96）以及合并症数量为1（比值比 = 5.69，95%置信区间1.59 - 20.41）与接受瑞德西韦治疗的确诊临床重症新冠病毒患者的预后之间存在关联。
本研究证实了年龄和合并症对印度尼西亚国家转诊医院接受瑞德西韦治疗的新冠病毒患者预后的重要性。本研究有助于患者治疗管理，可能降低发病率甚至患者死亡率。
